Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Baxdrostat by AstraZeneca for Resistant Hypertension: Likelihood of Approval
Baxdrostat is under clinical development by AstraZeneca and currently in Phase III for Resistant Hypertension. According to GlobalData, Phase III...
Baxdrostat by AstraZeneca for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
Baxdrostat is under clinical development by AstraZeneca and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure). According...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Baxdrostat?
Baxdrostat is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Resistant Hypertension. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Baxdrostat?
Baxdrostat is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Resistant Hypertension. According to Globaldata,...